RxDoctor Payments Data

Elliot Lederman, MD

Internal Medicine · Brooklyn, NYNPI 1134284284

Payments from drug & device makers

$397,371in general payments, 2019–2025

Across 80 payments — averaging $4967.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron$285K
  • Pfizer$112K
  • Boehringer Ingelheim$213
  • Lilly USA, LLC$152
  • Exact Sciences$103
  • Amgen$78
  • plus $185 from 6 others

What the payments were for

  • Food & beverage$732100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Regeneron36$284,651
Pfizer8$111,988
Boehringer Ingelheim10$213
Lilly USA, LLC7$152
Exact Sciences4$103
Amgen(2 entities)4$78
AbbVie(2 entities)3$52
Merck3$45
AstraZeneca2$26
Bayer1$24
Amarin Pharma, Inc.1$20
Shire North American Group Inc1$18

How this compares

$397,371 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$39,061
Medicare patients
108
Services billed
501

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate70$71,497
JardianceEmpagliflozin46$53,056
EliquisApixaban56$47,160
XareltoRivaroxaban30$19,460
VascepaIcosapent Ethyl44$15,119
OzempicSemaglutide14$13,338
Dexlansoprazole DrDexlansoprazole18$4,157
Atorvastatin Calcium447$3,925
Diclofenac Sodium22$3,499
Amlodipine Besylate630$3,479
Losartan Potassium385$2,883
SynthroidLevothyroxine Sodium33$2,369
Albuterol Sulfate HfaAlbuterol Sulfate68$1,910
Rosuvastatin Calcium123$1,842
Metoprolol Succinate149$1,832

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$45$71,49770 claims
Boehringer IngelheimJardiance$213$53,05646 claims
PfizerEliquis$111,988$47,16056 claims
AbbVieSynthroid$52$2,36933 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →